SUMO化通路及其抑制剂研究概述
Overview of the SUMO-Chemical Pathway and Its Inhibitors
DOI: 10.12677/BP.2022.121003, PDF,   
作者: 于祥旭, 陆美玲*：中国药科大学生命科学与技术学院，江苏 南京
关键词: SUMO；SUMO化；蛋白修饰；抑制剂；癌症； SUMO； SUMOylation； Protein Modification； Inhibitor； Cancer
摘要: SUMO化(SUMOylation)是一种可逆的翻译后修饰，是一种重要的分子调控机制，参与调控DNA损伤修复、免疫反应、癌变、细胞周期进程和细胞凋亡。现在已经发现了四种SUMO亚型，分别是SUMO1、SUMO2/3和SUMO4。小泛素样修饰物(SUMO)通路在所有真核生物中都是保守的，在基因表达调控、细胞信号转导和基因组完整性的维持中起着关键作用。SUMO的催化循环包括成熟、活化、偶联、连接和去修饰。SUMO系统的失调与许多疾病有关，特别是癌症。SUMO化修饰广泛参与肿瘤的癌变、DNA损伤反应、癌细胞的增殖、转移和凋亡。SUMO可以作为癌症的潜在治疗靶点。为了更好地理解SUMO在人类疾病中的作用，我们简要概述了SUMO系统的基本概念，并总结了SUMO蛋白在癌细胞中的作用以及最近关于这一通路的抑制剂研究进展。
Abstract: SUMOylation, a reversible modification after translation, is a kind of molecular regulation mechanism which participated in the regulation of DNA damage repair, immune reaction, process of cancerous cell cycle and cell apoptosis. Four subtypes of SUMO have been found, including SUMO1 SUMO2/3 and SUMO4. The small ubiquitin like modification (SUMO) pathway is conserved in all eukaryotes and plays a key role in gene expression regulation of cellular signal transduction and maintenance of genomic integrity. Dysregulation of the SUMO catalytic cycle has been associated with many diseases, especially cancer. In order to better understand the role of SUMO in human disease, we briefly outline the basic concepts of the SUMO system and summarize the role of SUMO proteins in cancer cells and the advances in inhibitors of this pathway.
文章引用：于祥旭, 陆美玲. SUMO化通路及其抑制剂研究概述[J]. 生物过程, 2022, 12(1): 20-25. https://doi.org/10.12677/BP.2022.121003

参考文献

[1] Bettermann, K., Benesch, M., Weis, S. and Haybaeck, J. (2012) SUMOylation in Carcinogenesis. Cancer Letters, 316, 113-125.
[2] Eifler, K. and Vertegaal, A.C.O. (2015) SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. Trends in Biochemical Sciences, 40, 779-793. [Google Scholar] [CrossRef] [PubMed]
[3] Flotho, A. and Melchior, F. (2013) SUMOylation: A Regulatory Protein Modification in Health and Disease. Annual Review of Biochemistry, 82, 357-385. [Google Scholar] [CrossRef] [PubMed]
[4] Rabellino, A., Andreani, C. and Scaglioni, P.P. (2017) The Role of PIAS SUMO E3-Ligases in Cancer. Cancer Research, 77, 1542-1547. [Google Scholar] [CrossRef] 
[5] Seeler, J.S. and Dejean, A. (2017) SUMO and the Ro-bustness of Cancer. Nature Reviews Cancer, 17, 184-197. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, Y. and Dasso, M. (2009) SUMOylation and deSUMOylation at a Glance. Journal of Cell Science, 122, 4249-1252. [Google Scholar] [CrossRef] [PubMed]
[7] Mahajan, R., Delphin, C., Guan, T., Gerace, L. and Melchior, F. (1997) A Small Ubiquitin-Related Polypeptide Involved in Targeting RanGAP1 to Nuclear Pore Complex Protein RanBP2. Cell, 88, 97-107. [Google Scholar] [CrossRef] 
[8] Matunis, M.J., Coutavas, E. and Blobel, G. (1996) A Novel Ubiquitin-Like Modification Modulates the Partitioning of the Ran-GTPase-Activating Protein RanGAP1 between the Cytosol and the Nuclear Pore Complex. Journal of Cell Biology, 135, 1457-1470. [Google Scholar] [CrossRef] [PubMed]
[9] Saitoh, H. and Hinchey, J. (2000) Functional Heterogeneity of Small Ubiquitin-Related Protein Modifiers SUMO-1 versus SUMO-2/3. Journal of Biological Chemistry, 275, 6252-6258. [Google Scholar] [CrossRef] [PubMed]
[10] Nayak, A. and Müller, S. (2014) SUMO-Specific Proteas-es/Isopeptidases: SENPs and beyond. Genome Biology, 15, Article No. 422. [Google Scholar] [CrossRef] [PubMed]
[11] Desterro, J.M., Rodriguez, M.S., Kemp, G.D. and Hay, R.T. (1999) Identification of the Enzyme Required for Activation of the Small Ubiquitin-Like Protein SUMO-1. Journal of Biological Chemistry, 274, 10618-10624. [Google Scholar] [CrossRef] [PubMed]
[12] Tatham, M.H., Kim, S., Jaffray, E., Song, J., Chen, Y. and Hay, R.T. (2005) Unique Binding Interactions among Ubc9, SUMO and RanBP2 Reveal a Mechanism for SUMO Paralog Selection. Nature Structural & Molecular Biology, 12, 67-74. [Google Scholar] [CrossRef] [PubMed]
[13] Ber-nier-Villamor, V., Sampson, D.A., Matunis, M.J. and Lima, C.D. (2002) Structural Basis for E2-Mediated SUMO Con-jugation Revealed by a Complex between Ubiquitin-Conjugating Enzyme Ubc9 and RanGAP1. Cell, 108, 345-356. [Google Scholar] [CrossRef] 
[14] Werner, A., Flotho, A. and Melchior, F. (2012) The RanBP2/RanGAP1*SUMO1/Ubc9 Complex Is a Multisubunit SUMO E3 Ligase. Molecular Cell, 46, 287-298. [Google Scholar] [CrossRef] [PubMed]
[15] Jackson, S.P. and Durocher, D. (2013) Regulation of DNA Damage Responses by Ubiquitin and SUMO. Molecular Cell, 49, 795-807. [Google Scholar] [CrossRef] [PubMed]
[16] Sarangi, P. and Zhao, X. (2015) SUMO-Mediated Regulation of DNA Damage Repair and Responses. Trends in Biochemical Sciences, 40, 233-242. [Google Scholar] [CrossRef] [PubMed]
[17] Moschos, S.J., Jukic, D.M., Athanassiou, C., Bhargava, R., Dacic, S., Wang, X., Kuan, S.F., Fayewicz, S.L., Galambos, C., Acquafondata, M., Dhir, R. and Becker, D. (2010) Expression Analysis of Ubc9, the Single small Ubiquitin-Like Modifier (SUMO) E2 Conjugating Enzyme, in Normal And Malig-nant Tissues. Human Pathology, 41, 1286-1298. [Google Scholar] [CrossRef] [PubMed]
[18] Zhu, S., Sachdeva, M., Wu, F., Lu, Z. and Mo, Y.Y. (2010) Ubc9 Promotes Breast Cell Invasion and Metastasis in a SUMOylation-Independent Manner. Oncogene, 29, 1763-1772. [Google Scholar] [CrossRef] [PubMed]
[19] He, X., Riceberg, J., Pulukuri, S.M., Grossman, S., Shinde, V., Shah, P., Brownell, J.E., Dick, L., Newcomb, J. and Bence, N. (2015) Characterization of the Loss of SUMO Pathway Func-tion on Cancer Cells and Tumor Proliferation. PLoS ONE, 10, e0123882. [Google Scholar] [CrossRef] [PubMed]
[20] Kessler, J.D., Kahle, K.T., Sun, T., Meerbrey, K.L., Schlabach, M.R., Schmitt, E.M., Skinner, S.O., Xu, Q., Li, M.Z., Hartman, Z.C., Rao, M., Yu, P., Dominguez-Vidana, R., Liang, A.C., Solimini, N.L., Bernardi, R.J., Yu, B., Hsu, T., Golding, I., Luo, J., Osborne, C.K., Creighton, C.J., Hilsenbeck, S.G., Schiff, R., Shaw, C.A., Elledge, S.J. and Westbrook, T.F. (2012) A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis. Science, 335, 348-353. [Google Scholar] [CrossRef] [PubMed]
[21] Sabò, A., Doni, M. and Amati, B. (2014) SUMOylation of Myc-Family Proteins. PLoS ONE, 9, e91072. [Google Scholar] [CrossRef] [PubMed]
[22] Evan, G. (2012) Cancer. Taking a Back Door to Target Myc. Science, 335, 293-294. [Google Scholar] [CrossRef] [PubMed]
[23] Schimmel, J., Eifler, K., Sigurðsson, J.O., Cuijpers, S.A., Hendriks, I.A., Verlaan-de Vries, M., Kelstrup, C.D., Francavilla, C., Medema, R.H., Olsen, J.V. and Vertegaal, A.C. (2014) Un-covering SUMOylation Dynamicsduring Cell-Cycle Progression Reveals FoxM1 as a Key Mitotic SUMO Target Protein. Molecular Cell, 53, 1053-1066. [Google Scholar] [CrossRef] [PubMed]
[24] Wierstra, I. (2013) FOXM1 (Forkhead Box M1) in Tumorigen-esis: Overexpression in Human Cancer, Implication in Tumorigenesis, Oncogenic Functions, Tumor-Suppressive Prop-erties, and Target of Anticancer Therapy. Advances in Cancer Research, 119, 191-419. [Google Scholar] [CrossRef] 
[25] Myatt, S.S., Kongsema, M., Man, C.W., Kelly, D.J., Gomes, A.R., Khongkow, P., Karunarathna, U., Zona, S., Langer, J.K., Dunsby, C.W., Coombes, R.C., French, P.M., Brosens, J.J. and Lam, E.W. (2013) SUMOylation Inhibits FOXM1 Activity and Delays Mitotic Transition. Oncogene, 33, 4316-4329. [Google Scholar] [CrossRef] [PubMed]
[26] Gostissa, M., Hengstermann, A., Fogal, V., Sandy, P., Schwarz, S.E., Scheffner, M. and Del Sal, G. (1999) Activation of p53 by Conjugation to the Ubiquitin-Like Protein SUMO-1. The EMBO Journal, 18, 6462-6471.
[27] Muller, S., Berger, M., Lehembre, F., Seeler, J.S., Haupt, Y. and Dejean, A. (2000) c-Jun and p53 Activity Is Modulated by SUMO-1 Modification. Journal of Biological Chemistry, 275, 13321-13329. [Google Scholar] [CrossRef] [PubMed]
[28] Comerford, K.M., Leonard, M.O., Karhausen, J., Carey, R., Colgan, S.P. and Taylor, C.T. (2003) Small Ubiquitin-Related Modifier-1 Modification Mediates Resolution of CREB-Dependent Responses to Hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 100, 986-991. [Google Scholar] [CrossRef] [PubMed]
[29] Yang, Y., Xia, Z., Wang, X., Zhao, X., Sheng, Z., Ye, Y., He, G., Zhou, L., Zhu, H., Xu, N. and Liang, S. (2018) Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel An-ticancer Compounds. Molecular Pharmacology, 94, 885-894.
[30] Shanmugam, M.K., Garg, M., Makhija, P., Kumar, A.P., Sharifi-Rad, J., Zam, W. and Bishayee, A. (2021) Ginkgolic Acids Confer Potential Anticancer Effects by Target-ing Pro-Inflammatory and Oncogenic Signaling Molecules. Current Molecular Pharmacology, 14, 806-822. [Google Scholar] [CrossRef] [PubMed]
[31] Liu, D., Li, Z., Yang, Z., Ma, J. and Mai, S. (2021) Ginkgoic Acid Impedes Gastric Cancer Cell Proliferation, Migration and EMT through Inhibiting the SUMOylation of IGF-1R. Chemico-Biological Interactions, 337, Article ID: 109394. [Google Scholar] [CrossRef] [PubMed]
[32] He, X., Riceberg, J., Soucy, T., Koenig, E., Minissale, J., Gallery, M., Bernard, H., Yang, X., Liao, H., Rabino, C., Shah, P., Xega, K., Yan, Z.H., Sintchak, M., Bradley, J., Xu, H., Duffey, M., England, D., Mizutani, H., Hu, Z., Guo, J., Chau, R., Dick, L.R., Brownell, J.E., Newcomb, J., Langston, S., Lightcap, E.S., Bence, N. and Pulukuri, S.M. (2017) Probing the Roles of SUMOylation in Cancer Cell Biology by Us-ing A Selective SAE Inhibitor. Nature Chemical Biology, 13, 1164-1171. [Google Scholar] [CrossRef] [PubMed]
[33] Li, Y.J., Du, L., Wang, J., Vega, R., Lee, T.D., Miao, Y., Al-dana-Masangkay, G., Samuels, E.R., Li, B., Ouyang, S.X., Colayco, S.A., Bobkova, E.V., Divlianska, D.B., Sergienko, E., Chung, T.D.Y., Fakih, M. and Chen, Y. (2019) Allosteric Inhibition of Ubiquitin-Like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. Cell Chemical Biology, 26, 278-288.E6. [Google Scholar] [CrossRef] [PubMed]
[34] Biederstädt, A., Hassan, Z., Schneeweis, C., Schick, M., Schneider, L., Muckenhuber, A., Hong, Y., Siegers, G., Nilsson, L., Wirth, M., Dantes, Z., Steiger, K., Schunck, K., Langston, S., Lenhof, H.P., Coluccio, A., Orben, F., Slawska, J., Scherger, A., Saur, D., Müller, S., Rad, R., Weichert, W., Nilsson, J., Reichert, M., Schneider, G. and Keller, U. (2020) SUMO Pathway Inhibition Targets an Aggressive Pancreatic Cancer Subtype. Gut, 69, 1472-1482. [Google Scholar] [CrossRef] [PubMed]
[35] Langston, S.P., Grossman, S., England, D., Afroze, R., Bence, N., Bowman, D., Bump, N., Chau, R., Chuang, B.C., Claiborne, C., Cohen, L., Connolly, K., Duffey, M., Durvasula, N., Freeze, S., Gallery, M., Galvin, K., Gaulin, J., Gershman, R., Greenspan, P., Grieves, J., Guo, J., Gulavita, N., Hailu, S., He, X., Hoar, K., Hu, Y., Hu, Z., Ito, M., Kim, M.S., Lane, S.W., Lok, D., Lublinsky, A., Mallender, W., McIntyre, C., Minissale, J., Mizutani, H., Mizutani, M., Molchinova, N., Ono, K., Patil, A., Qian, M., Riceberg, J., Shindi, V., Sintchak, M.D., Song, K., Soucy, T., Wang, Y., Xu, H., Yang, X., Zawadzka, A., Zhang, J. and Pulukuri, S.M. (2021) Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer. Journal of Medicinal Chemistry, 64, 2501-2520. [Google Scholar] [CrossRef] [PubMed]
[36] Khattar, M., Grossman, S., Xega, K., et al. (2019) TAK-981: A First in Class SUMO Inhibitor in Phase 1 Trials that Promotes Dendritic Cell Activation, Antigen-Presentation, and T Cell Priming. Cancer Research, 79, Article No. 3252. [Google Scholar] [CrossRef] 
[37] Berger, A., Ghasemi, O., Grossman, S., et al. (2019) Pharmacodynamic Evaluation of the Novel SUMOylation Inhibitor TAK-981 in a Mouse Tumor Model. Cancer Re-search, 79, Article No. 3079. [Google Scholar] [CrossRef]